AIM This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use. METHODS A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. STRUCTURE Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.

中文翻译：

---

2020 年 AHA/ACC 肥厚型心肌病患者诊断和治疗指南：执行摘要

目的 肥厚型心肌病临床实践指南的执行摘要为临床医生诊断和管理成人和儿童患者的肥厚型心肌病提供了建议和算法，并提供了支持文件以鼓励其使用。方法 从 2010 年 1 月 1 日到 2020 年 4 月 30 日进行了全面的文献检索，包括 PubMed、EMBASE、Cochrane Collaboration、Agency for Healthcare Research 和质量报告和其他相关数据库。结构 早期肥厚型心肌病指南中的许多建议已根据新证据或对早期证据的更好理解进行了更新。本摘要将完整指南中的建议付诸实施，并结合了诊断检查、遗传和家庭筛查、风险分层方法、生活方式改变、手术和导管干预以及构成指南指导医学治疗组成部分的药物。对于指南指导的药物治疗和其他推荐的药物治疗方案，建议读者根据产品说明书材料遵循剂量、禁忌症和药物相互作用。